Aldosterone and its target the mineralocorticoid receptor are implied in development of cardiovascular disease such as arterial high blood pressure or cardiac failure. Serum aldosterone level is insufficient to know if the mineralocorticoid receptor is activated or not. The aim of this study is to identify biomarkers of mineralocorticoid receptor activity. The first "candidate biomarker" is Neutrophil gelatinase-associated lipocalin (NGAL) or "lipocalin" which being measured in blood or in the urine. According to scientific knowledge's evolution, others biomarkers could be tested later thanks to the blood or urinary samples taken during study.
This study is broken up into 5 groups: The first is a pre-analytical study to determinate optimum conditions for lipocalin samples. The second focuses on intra-individual variations of lipocalin levels in blood and urine. The third determinate the normal values of lipocalin in blood and urine. Fourthly, we study the role of renal function on serum and urines lipocalin levels. Fifthly, we study the role of anti-aldosterone treatment on patients who suffer of primary hyperaldosteronism.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
42
Blood test on an empty stomach. Urinary taking on arrival in the service
For the group 5, at the time of the V0 visit, a treatment by aldactone will be set up (posology: 1 to 2 mg/kg).
Brabois Hospital
Nancy, France
Georges Pompidou Hospital
Paris, France
Unit of arterial high blood pressure of the Georges Pompidou Hospital
Paris, France
Lipocalin blood and urinary concentrations
Serum and urinary lipocalin concentrations will be evaluated using comercially available kits (Kits lipocalin-2/NGAL (NCAL20))
Time frame: 8 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.